<DOC>
	<DOCNO>NCT02894554</DOCNO>
	<brief_summary>The hepatitis B virus ( HBV ) infection rate among renal transplant recipient report 3 % 20.9 % . And patient survival graft survival rate follow renal transplantation may worsen HBsAg-positive carrier HBsAg-negative recipient . Due viral replication asymptomatic HBV carrier induce post-transplant immunosuppression , liver-related complication , liver failure bleeding , account 37 % 57 % mortality case HBsAg-positive renal allograft recipient . Since late 1990s , Lamivudine recognize effective well-tolerated antiviral drug chronic HBV infection . Lamivudine treatment among HBsAg-positive renal allograft recipient significantly improve patient survival rate short-term follow-up . Telbivudine another approved nucleoside antiviral agent patient chronic hepatitis B ( CHB ) . Recently , show eGFR improve HBV-related decompensated cirrhosis patient 52 week Telbivudine treatment . Additional eGFR increase also observe Lamivudine experience CHB patient switch Telbivudine treatment . However , limited result know renal function affect oral anti-HBV drug patient receive kidney transplantation . Therefore , would like conduct study evaluate renal function Lamivudine long term use HBsAg positive patient receive kidney transplantation switch Telbivudine treatment . The clinical virological outcome provide valuable insight clinical practice .</brief_summary>
	<brief_title>Renal Function Improvement HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Kidney transplant patient treat Lamivudine 6 month ( Considering include post kidney transplantation &gt; 6 month stable calcineurin inhibitor level 2 . Seropositive HBsAg 6 month 3 . Willing able provide write informed consent 1 . Hepatitis cirrhosis patient 2 . Coinfection hepatitis C virus HIV 3 . Pregnant nursing 4 . YMDD resistant baseline 5 . ABO incompatible renal transplantation 6 . Cross match positive 7 . Poor renal function baseline ( eGFR &lt; 20 ) 8 . Known hypersensitivity intolerance ingredient Telbivudine 9 . Known history Telbivudine resistance</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>